IU “Icons” Fireside Chat with Dr. Richard DiMarchi of Indiana University
11:00 – 11:45am
Alumni Hall – Indiana Memorial Union
Richard DiMarchi– Hosted by David Johnson
IU Ventures is proud to welcome Dr. Richard DiMarchi, one of Indiana University’s “iconic” alumni and faculty, to this year’s Summit.
Richard DiMarchi is a Distinguished Professor of Chemistry and Gill Chair in Biomolecular Sciences at Indiana University. Dr. DiMarchi is a member of the National Academy of Medicine and the National Inventors Hall of Fame. He is a former Group Vice President at Eli Lilly and later at Novo Nordisk. He is recognized for his contributions to the discovery and development of rDNA-derived Humalog®, rGlucagon®, and Forteo®. His academic research has broadened the understanding of glucagon physiology and the discovery of single molecule multimode agonists for the treatment of diabetes and obesity.
Professor DiMarchi is co-inventor on more than one hundred U.S. patents and co-author to more than two hundred fifty peer-reviewed scientific publications. He was identified as a top five translation researcher by Nature Biotechnology. Since 2003, he has co-founded eight successful biotech companies. In the last decade Professor DiMarchi has received numerous awards such as the Merrifield Award for career contributions in peptide sciences, the German National Erwin Schrödinger-Preis, the Alfred Burger career award in medicinal chemistry, and the 2023 AAAS Bhaumik Breakthrough Award for his contribution to the transformative advance in drug treatment of obesity.
This fireside chat will be hosted by David Johnson.
David L. Johnson is the president of Regional Growth Strategies LLC, a consulting practice working with communities, universities and foundations seeking to grow and sustain technology-based regional economies.
Johnson has been involved in the hands-on work of economic development for nearly 25 years. He began this engagement as a community volunteer, seeking to organize and then co-founding Indiana’s life sciences initiative, BioCrossroads, in 2001-2002. Johnson went on to serve as BioCrossroads CEO from 2005-2018. There, he organized and led the capitalization of five seed and early-stage venture capital funds to support locally based life sciences start-ups.
More recently and also as CEO, Johnson led the Central Indiana Corporate Partnership (CICP), a collaborative organization of chief executives drawn from leading Indiana companies, universities and philanthropic foundations (and the parent organization of BioCrossroads), from 2012 through 2022.
Johnson was appointed to serve as a Non-Resident Senior Fellow for the Brookings Institution’s Metropolitan Policy Program in 2023.